Carisma’s Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma: Promising Pre-Clinical Data Revealed!
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC)
PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, “CAR-M”) therapy for hepatocellular carcinoma (“HCC”), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully create CAR-M directly in vivo, reprogramming endogenous myeloid cells to target and destroy Glypican-3 (“GPC3”), expressing cancer cells.
Carisma Therapeutics Inc., in collaboration with Moderna, Inc., has unveiled groundbreaking pre-clinical data on their anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC). This innovative therapy has shown promising results in reprogramming the body’s own myeloid cells to effectively target and eliminate cancer cells expressing Glypican-3.
The use of CAR-M technology represents a significant advancement in the field of immunotherapy, offering a potential off-the-shelf treatment option for patients with HCC. By harnessing the power of the body’s immune system to fight cancer, this therapy holds great promise in improving outcomes for individuals battling this deadly disease.
With the successful development of a candidate that can create CAR-M directly in vivo, Carisma and Moderna have paved the way for a new approach to treating HCC. By targeting GPC3-expressing cancer cells, this therapy has the potential to revolutionize the way we think about and treat hepatocellular carcinoma.
How will this affect me?
If you or a loved one are diagnosed with hepatocellular carcinoma, the emergence of Carisma’s Anti-GPC3 In Vivo CAR-M Therapy could offer a new ray of hope. This innovative treatment has shown promising results in pre-clinical studies, indicating its potential to become a safe and effective therapy for HCC patients. Keep an eye on further developments in this exciting area of research, as it may hold the key to improved outcomes and quality of life for individuals battling this deadly disease.
How will this affect the world?
The introduction of Carisma’s Anti-GPC3 In Vivo CAR-M Therapy represents a significant milestone in the field of cancer treatment. By harnessing the power of the immune system to target and destroy cancer cells, this therapy has the potential to revolutionize the way we approach and manage hepatocellular carcinoma. As further clinical trials are conducted and the therapy is potentially brought to market, it could have a profound impact on the global fight against HCC, offering new hope to patients worldwide.
Conclusion
The positive pre-clinical data on Carisma’s Anti-GPC3 In Vivo CAR-M Therapy for hepatocellular carcinoma is a promising step forward in the field of cancer immunotherapy. By reprogramming the body’s own immune cells to target and destroy cancer cells, this innovative therapy offers new hope for patients with HCC. As further research and clinical trials are conducted, we may see this therapy become a game-changer in the fight against hepatocellular carcinoma, potentially improving outcomes and quality of life for individuals worldwide.
